Professional
Added to YB: 2025-02-14
Pitch date: 2025-01-26
LQDA [bullish]
Liquidia Corporation
+452.76%
current return
Author Info
No bio for this author
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$6.0B
Pitch Price
$14.33
Price Target
N/A
Dividend
N/A
EV/EBITDA
125.43
P/E
278.59
EV/Sales
20.86
Sector
Pharmaceuticals
Category
special_situation
Arquitos Capital Management Portfolio Holding: Liquidia Corporation
LQDA: FDA approval for Yutrepia expected May 2025. Superior to UTHR's Tyvaso in PAH/PH-ILD treatment. Clinical data shows 33 bps vs 9-12 bps, better outcomes. $1.7B market, 4x growth in 5 years. $1B market cap, multiples higher potential post-launch. Buyout possible within a year.
Read full article (4 min)